Syndax Announces Participation in September Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

Citi 2026 Biopharma Back to School Conference in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.
H.C. Wainwright 28th Annual Global Investment Conference in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET.
Syndax Announces Participation in September Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- Citi 2026 Biopharma Back to School Conference in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.
- H.C. Wainwright 28th Annual Global Investment Conference in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET.
  
  Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline
  
  Fri, 21 Aug 2026 07:39:18 -0400
  
  UBS analyst David Dai lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $33.00 (from $37.00) while maintaining a Buy rating.
  The analyst commented, "In 2Q26, while new Revuforj patient starts decline to ~250 (vs. ~330 in 1Q), maintenance patients increased to ~169 in 2Q (vs. ~44 in 1Q) based on our estimates. We view the increased maintenance patients as encouraging. Based on discussion with mgmt, we expect new patient starts to recover in 2H and we estimate ~330 in 3Q26 and ~413 in 4Q26, including ~132/~161 NPM1m and ~198/~253 KMT2Ar patients, respectively. Together with increasing post-HSCT maintenance use, we estimate Revuforj
  
  Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline
  
  Fri, 21 Aug 2026 07:39:18 -0400
  
  UBS analyst David Dai lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $33.00 (from $37.00) while maintaining a Buy rating.
  The analyst commented, "In 2Q26, while new Revuforj patient starts decline to ~250 (vs. ~330 in 1Q), maintenance patients increased to ~169 in 2Q (vs. ~44 in 1Q) based on our estimates. We view the increased maintenance patients as encouraging. Based on discussion with mgmt, we expect new patient starts to recover in 2H and we estimate ~330 in 3Q26 and ~413 in 4Q26, including ~132/~161 NPM1m and ~198/~253 KMT2Ar patients, respectively. Together with increasing post-HSCT maintenance use, we estimate Revuforj
  
  Syndax Pharmaceuticals (SNDX) PT Lowered to $40 at JPMorgan
  
  Tue, 11 Aug 2026 08:49:28 -0400
  JPMorgan analyst Anupam Rama lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $40.00 (from $44.00) while maintaining a Overweight rating.
  
  Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: STATE STREET CORP
  
  Fri, 07 Aug 2026 11:00:00 -0400
  si-local-file:///var/storage/secattach/20260807/26889223.html
  
  Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: STATE STREET CORP
  
  Fri, 07 Aug 2026 11:00:00 -0400
  si-local-file:///var/storage/secattach/20260807/26889223.html
  
  Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  
  Wed, 05 Aug 2026 16:01:00 -0400
  
  NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through
  
  Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  
  Wed, 05 Aug 2026 16:01:00 -0400
  
  NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through
  
  Syndax Pharmaceuticals (SNDX) PT Lowered to $38 at H.C. Wainwright
  
  Wed, 05 Aug 2026 06:37:49 -0400
  H.C. Wainwright analyst Andres Maldonado lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $38.00 (from $40.00) while maintaining a Buy rating.
  
  Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at BofA Securities
  
  Wed, 05 Aug 2026 05:08:43 -0400
  
  BofA Securities analyst Jason Zemansky lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $26.00 (from $29.00) while maintaining a Buy rating.
  The analyst comments "We look for SNDX shares to trade lower after a disappointing 2Q print, marked by misses on the top- (-$6M vs. BB cons) and bottom-lines (-$0.08), with Revuforj well below (-$5M). Particularly after 1Q’s miss (see our: 1Q takes), today’s update is likely to prompt more concerns over the menin class, which has yet to live up to initial lofty expectations. We recognize the concerns but would caution against negative readthroughs to the broader outlook
  
  Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at BofA Securities
  
  Wed, 05 Aug 2026 05:08:43 -0400
  
  BofA Securities analyst Jason Zemansky lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $26.00 (from $29.00) while maintaining a Buy rating.
  The analyst comments "We look for SNDX shares to trade lower after a disappointing 2Q print, marked by misses on the top- (-$6M vs. BB cons) and bottom-lines (-$0.08), with Revuforj well below (-$5M). Particularly after 1Q’s miss (see our: 1Q takes), today’s update is likely to prompt more concerns over the menin class, which has yet to live up to initial lofty expectations. We recognize the concerns but would caution against negative readthroughs to the broader outlook
  
  Syndax Pharmaceuticals (SNDX) Misses Q2 EPS by 7c
  
  Tue, 04 Aug 2026 16:10:42 -0400
  
  Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.55), $0.07 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $73 million versus the consensus estimate of $79.8 million.
  For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.
  
  Form 10-Q Syndax Pharmaceuticals For: Jun 30
  
  Tue, 04 Aug 2026 16:05:00 -0400
  si-local-file:///var/storage/secattach/20260804/26866048.html
  
  Form 10-Q Syndax Pharmaceuticals For: Jun 30
  
  Tue, 04 Aug 2026 16:05:00 -0400
  si-local-file:///var/storage/secattach/20260804/26866048.html
  
  Form 8-K Syndax Pharmaceuticals For: Aug 04
  
  Tue, 04 Aug 2026 16:03:00 -0400
  si-local-file:///var/storage/secattach/20260804/26865930.html
  
  Form 8-K Syndax Pharmaceuticals For: Aug 04
  
  Tue, 04 Aug 2026 16:03:00 -0400
  si-local-file:///var/storage/secattach/20260804/26865930.html
  
  Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
  
  Tue, 04 Aug 2026 16:01:00 -0400
  
  – Total revenue of $73 million in 2Q26, a 92% year-over-year increase –
  
  – Revuforj^® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase –
  
  – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million –
  
  – Expanded pipeline with a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and an internally developed next-generation menin inhibitor for myelofibrosis –
  
  – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD –
  
  Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
  
  Tue, 04 Aug 2026 16:01:00 -0400
  
  – Total revenue of $73 million in 2Q26, a 92% year-over-year increase –
  
  – Revuforj^® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase –
  
  – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million –
  
  – Expanded pipeline with a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and an internally developed next-generation menin inhibitor for myelofibrosis –
  
  – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD –
  
  Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
  
  Tue, 28 Jul 2026 07:00:00 -0400
  
  NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026.
  
  In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 4, 2026.
  
  The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the
  
  Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
  
  Tue, 28 Jul 2026 07:00:00 -0400
  
  NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026.
  
  In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 4, 2026.
  
  The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the
  
  H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
  
  Wed, 15 Jul 2026 07:38:43 -0400
  
  H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $40.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).
  The analyst commented: "Yesterday, we attended Syndax’s R&D Day, which showcased two new assets, SNDX-62122 and SNDX-4321, that we believe could provide meaningful long-term value creation beyond the established Revuforj and Niktimvo franchises. SNDX-62122 is an internally developed, next-generation menin inhibitor being advanced initially in myelofibrosis and designed to offer higher potency, improved selectivity, optimized pharmacokinetics, and a potentially more combinable profile than parent molecule revumenib. Compelling preclinical data identified menin as a novel dependency in the atypical megakaryocytes and early megakaryocyte progenitors
  
  Form 8-K Syndax Pharmaceuticals For: Jul 14
  
  Tue, 14 Jul 2026 08:31:00 -0400
  si-local-file:///var/storage/secattach/20260714/26765386.html
  
  Form 8-K Syndax Pharmaceuticals For: Jul 14
  
  Tue, 14 Jul 2026 08:31:00 -0400
  si-local-file:///var/storage/secattach/20260714/26765386.html
  
  Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
  
  Tue, 14 Jul 2026 08:00:00 -0400
  
  – Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –
  
  – SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –
  
  – SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –
  
  – Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –
  
  – R&D Event featuring three

StreetInsider.com News Articles

Syndax Announces Participation in September Investor Conferences

Syndax Announces Participation in September Investor Conferences

Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline

Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline

Syndax Pharmaceuticals (SNDX) PT Lowered to $40 at JPMorgan

Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: STATE STREET CORP

Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: STATE STREET CORP

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals (SNDX) PT Lowered to $38 at H.C. Wainwright

Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at BofA Securities

Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at BofA Securities

Syndax Pharmaceuticals (SNDX) Misses Q2 EPS by 7c

Form 10-Q Syndax Pharmaceuticals For: Jun 30

Form 10-Q Syndax Pharmaceuticals For: Jun 30

Form 8-K Syndax Pharmaceuticals For: Aug 04

Form 8-K Syndax Pharmaceuticals For: Aug 04

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Form 8-K Syndax Pharmaceuticals For: Jul 14

Form 8-K Syndax Pharmaceuticals For: Jul 14

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event